Scientific and industrial status of tissue engineering

African Journal of Biotechnology

Volumn 6, Issue 25, 2007, Pages 2897-2909

  Samadikuchaksaraei, Ali ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Developing countries; Economics; Health care sector; Health planning; Marketing; Regenerative medicine; Research; Tissue engineering

Indexed keywords

BIOMATERIAL;

ARTIFICIAL ORGAN; BIOCOMPATIBILITY; BIOMECHANICS; DEVELOPING COUNTRY; DEVICE; EUROPE; INFORMATION SCIENCE; JAPAN; MARKETING; POLICY; REVIEW; TECHNOLOGY; TISSUE ENGINEERING; TREATMENT INDICATION; UNITED STATES;

EID: 38049177588     PISSN: None     EISSN: 16845315     Source Type: Journal    
DOI: 10.5897/ajb2007.000-2459     Document Type: Review

References (132)

1. Anon (2002). Report of the forum on technology, employment and poverty alleviation in the Arab countries, Beirut. New York, Economic and Social Commission for Western Asia, United Nations.
2. Anon (1999). News in Brief. Nature 397: 554-555.
3. Anon (2000). Diabetes Atlas. Brussels, International Diabetes Federation.
4. Anon (2001a). ChondroTec® -Report. Hamburg, Germany, CellTec GmbH (http://www.celltec.de/ct/all/doc/chondrotec_report_200103.pdf).
5. Anon (2001b). Tissue Engineering. Stuttgart, Landesbank Baden-Württemberg Equity Research.
6. Anon (2002a). ArthroMatrix® Autologe Chondrozyte Implantation. Arthrex Biosystems and Orthogen Therapeutics http://www.orthogen.com/en/ downloads/english/arthromatrix_engl.pdf).
7. Anon (2002b). Biomaterialien und Tissue Engineering am Neuen Markt. Frankfurt/M, CONCORD Corporate Finance Research, p. 91.
8. Anon (2003a). Market overview. New York (www.tissera.com), TissEra Inc.
9. Anon (2003b). The World Health Report 2003 - Shaping the Future. World Health Organization (WHO).
10. Anon (2004). Vital Therapies company overview. San Diego, Vital Therapies, Inc.
11. Anon (2005a). Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1995-2004. Rockville MD. U.S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation.
12. Anon (2005b). Preventing Chronic Diseases: a Vital Investment, Department of Chronic Diseases and Health Promotion, World Health Organization, Geneva, Switzerland.
13. Anon (2005c). Proposal for a Regulation of the European Parliament and of the Council on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Brussels, Belgium, European Commission Directorate General for Enterprise and Industry.
14. Anon (2005d). Treating Diabetes - DiabeCell®. Hawthorn, Victoria, Australia, Living Cell Technologies (LCT) Limited.
15. Anon (2006a). 2020: a new vision - a future for regenerative medicine. Washington, D.C. (www.hhs.gov/reference/newfuture.shtml), U.S. Department of Health and Human Services.
16. Anon (2006b). Mission: Center for Developmental Biology. Kobe, Japan (http://www.cdb.riken.jp), Research Promotion Division, RIKEN Kobe Institute.
17. Anon (2006c). The market for stem cell products. Oceanside, CA (www.InternationalStemCell.com), International Stem Cell Corporation.
18. AmCyte Inc (2005). (The AmCyte experience: perspectives on adult stem cells and encapsulation for the treatment of diabetes. BIO 2005 Business Forum. Philadelphia, Biotechnology Industry Organization. 2005.
19. Andereya S, Maus U, Gavenis K, Muller-Rath R, Miltner O, Mumme T, Schneider U (2006). [First clinical experiences with a novel 3D-collagen gel (CaReS) for the treatment of focal cartilage defects in the knee]. Z. Orthop. Ihre Grenzgeb. 144: 272-280.
20. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, Grunwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S, Zeiher AM (2002). Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 106: 3009-3017.
21. Baguneid MS, Seifalian AM, Salacinski HJ, Murray D, Hamilton G, Walker MG (2006). Tissue engineering of blood vessels. Br. J. Surg 93: 282-290.
22. Bakay RA, Raiser CD, Stover NP, Subramanian T, Cornfeldt ML, Schweikert AW, Allen RC, Watts R (2004). Implantation of Spheramine in advanced Parkinson's disease (PD). Front Biosci. 9: 592-602.
23. Beary III JF, Siegfried JD, Tavares R (1998). US Drug and Biologic Approvals in 1997. Drug Dev. Res. 44: 114-129.
24. Belenkov I, Ageev FT, Mareev VI, Savchenko VG (2003). [Mobilization of bone marrow stem cells in the management of patients with heart failure. Protocol and first results of ROT FRONT trial]. Kardiologiia. 43: 7-12.
25. Bello YM, Falabella AF, Eaglstein WH (2001). Tissue-engineered skin. Current status in wound healing. Am. J. Clin. Dermatol. 2: 305-313.
26. BioTissue Technologies AG (2002). BioSeed and BioSeed-M: Product description, technology and clinical evaluation. BioTissue Technologies AG (http://www. biotissue-tec.com).
27. Bobic V (2000). Tissue repair techniques of the future: options for articular cartilage injury. Medscape Orthop. Sports Med. 4: eJournal.
28. Bock AK, Ibarreta D, Rodriguez-Cerezo E (2003). Human tissue engineered products: today's market and future prospects; synthesis report. Report EUR 21000 EN. Seville, Spain, Institute for Prospective Technological Studies and European Commission Directorate General Joint Research Centre. Technical Report Series.
29. Bock AK, Rodriguez-Cerezo E, Hüsing B, Bührlen B, Nusser M (2005). Human tissue engineered products: potential socio-economic impacts of a new European regulatory framework for authorisation, supervision, and vigilance. Report EUR 21838 EN. Seville, Spain, Institute for Prospective Technological Studies and European Commission Directorate General Joint Research Centre. Technical Report Series.
30. Boutayeb A, Boutayeb S (2005). The burden of non communicable diseases in developing countries. Int. J. Equity Health 4: 2.
31. Britten MB, Abolmaali ND, Assmus B, Lehmann R, Honold J, Schmitt J, Vogl TJ, Martin H, Schachinger V, Dimmeler S, Zeiher AM (2003). Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation 108: 2212-2218.
32. Callera F, do Nascimento RX (2006). Delivery of autologous bone marrow precursor cells into the spinal cord via lumbar puncture technique in patients with spinal cord injury: a preliminary safety study. Exp. Hematol. 34: 130-131.
33. Caravaggi C, De Giglio R, Pritelli C, Sommaria M, Dalla NS, Faglia E, Mantero M, Clerici G, Fratino P, Dalla PL, Mariani G, Mingardi R, Morabito A (2003). HYAFF 11-based autologous dermal and epidermal grafts in the treatment of noninfected diabetic plantar and dorsal foot ulcers: a prospective, multicenter, controlled, randomized clinical trial. Diabetes Care 26: 2853-2859.
34. Cavorsi J, Vicari F, Wirthlin DJ, Ennis W, Kirsner R, O'connell SM, Steinberg J, Falanga V (2006). Best-practice algorithms for the use of a bilayered living cell therapy (Apligraf) in the treatment of lower-extremity ulcers. Wound. Repair Regen. 14: 102-109.
35. Choo V (2003). Philippines losing its nurses, and now maybe its doctors. Lancet 361: 1356.
36. Collins SW (2005). The Emerging Biomedical Innovation System in Kobe, Japan. Biotechnology in Japan. Seattle, Japan-America Society. 2005.
37. Compton CC, Gill JM, Bradford DA, Regauer S, Gallico GG, O'Connor NE (1989). Skin regenerated from cultured epithelial autografts on full-thickness burn wounds from 6 days to 5 years after grafting. A light, electron microscopic and immunohistochemical study. Lab Invest 60: 600-612.
38. Curran MP, Plosker GL (2002). Bilayered bioengineered skin substitute (Apligraf): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers. BioDrugs. 16: 439-455.
39. Demetriou AA, Brown RS, Busuttil RW, Fair J, McGuire BM, Rosenthal P, Am Esch JS, Lerut J, Nyberg SL, Salizzoni M, Fagan EA, de Hemptinne B, Broelsch CE, Muraca M, Salmeron JM, Rabkin JM, Metselaar HJ, Pratt D, De La MM, McChesney LP, Everson GT, Lavin PT, Stevens AC, Pitkin Z, Solomon BA (2004). Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann. Surg 239: 660-667.
40. Demetriou AA, Rozga J, Podesta L, Lepage E, Morsiani E, Moscioni AD, Hoffman A, McGrath M, Kong L, Rosen H (1995). Early clinical experience with a hybrid bioartificial liver. Scand. J. Gastroenterol. Suppl 208: 111-117.
41. Drobnic M, Kregar-Velikonja N, Radosavljevic D, Gorensek M, Koritnik B, Malicev E, Wozniak G, Jeras M, Knezevic M (2002). The outcome of autologous chondrocyte transplantation treatment of cartilage lesions in the knee. Cell Mol. Biol. Lett. 7: 361-363.
42. Eaglstein WH, Falanga V (1997). Tissue engineering and the development of Apligraf, a human skin equivalent. Clin. Ther. 19: 894-905.
43. Ellis AJ, Hughes RD, Wendon JA, Dunne J, Langley PG, Kelly JH, Gislason GT, Sussman NL, Williams R (1996). Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 24: 1446-1451.
44. Erggelet C, Sittinger M, Lahm A (2003). The arthroscopic implantation of autologous chondrocytes for the treatment of full-thickness cartilage defects of the knee joint. Arthroscopy 19: 108-110.
45. Fernández-Avilés F (2006). The Valladolid intracoronary bone marrow experience. Sherman W. Second International Conference on Cell Therapy for Cardiovascular Diseases. New York, New York Academy of Medicine.
46. Feron F, Perry C, Cochrane J, Licina P, Nowitzke A, Urquhart S, Geraghty T, Mackay-Sim A (2005). Autologous olfactory ensheathing cell transplantation in human spinal cord injury. Brain 128: 2951-2960.
47. Folch E, Hernandez I, Barragan M, Franco-Paredes C (2003). Infectious diseases, non-zero-sum thinking, and the developing world. Am. J. Med Sci. 326: 66-72.
48. Gaissmaier C, Fritz J, Schewe B, Albrecht D, Weise K (2005). Development of a novel collagen-based biphasic carrier for matrix-assisted transplantation of autologous chondrocytes. Akt. Traumatol. 35: 267-273.
49. Gaissmaier C, Fritz J, Schewe B, Albrecht D, Weise K, Stoop R, Fink U, Giordano N, Ashammakhi N, Aicher WK (2006). In: Zanasi S, Brittberg M, Marcacci M, Cancedda R (eds) Basic Science, Clinical Repair and Reconstruction of Articular Cartilage Defects: Current Status and Prospects, Timeo Editore Srl, Bologna, Italy.
50. Gentzkow GD, Iwasaki SD, Hershon KS, Mengel M, Prendergast JJ, Ricotta JJ, Steed DP, Lipkin S (1996). Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 19: 350-354.
51. Ghodsizad A, Klein HM, Borowski A, Stoldt V, Feifel N, Voelkel T, Piechaczek C, Burchardt E, Stockschlader M, Gams E (2004). Intraoperative isolation and processing of BM-derived stem cells. Cytotherapy. 6: 523-526.
52. Greenwood H, Thorsteinsdóttir H, Perry G, Renihan J, Singer PA, Daar AS (2006). Regenerative medicine: new opportunities for developing countries. Int. J. Biotechnol. 8: 60-77.
53. Grifka J, Anders S, Löhnert J, Baag R, Feldt S (2000). Regeneration von Gelenkknorpel durch die autologe Chondrozytentransplantation. Arthroskopie 13: 113-122.
54. Grikscheit TC, Vacanti JP (2002). The history and current status of tissue engineering: The future of pediatric surgery. J. Pediatr. Surg. 37: 277-288.
55. Grosset D, Grosset K (2005). Spheramine Titan/Schering. Curr. Opin. Investig. Drugs. 6: 722-728.
56. Hagege AA, Marolleau JP, Vilquin JT, Alheritiere A, Peyrard S, Duboc D, Abergel E, Messas E, Mousseaux E, Schwartz K, Desnos M, Menasche P (2006). Skeletal myoblast transplantation in ischemic heart failure: long-term follow-up of the first phase I cohort of patients. Circulation 114: I108-I113.
57. Harding S, Morris H, Patel G (2002). Healing chronic wounds. BMJ 324: 163.
58. Hare JM (2006). Mesenchymal cells in acute MI: preliminary results phase 1 study. Sherman W. Second International Conference on Cell Therapy for Cardiovascular Diseases. New York, New York Academy of Medicine.
59. Heimbach DM, Warden GD, Luterman A, Jordan MH, Ozobia N, Ryan CM, Voigt DW, Hickerson WL, Saffle JR, DeClement FA, Sheridan RL, Dimick AR (2003). Multicenter postapproval clinical trial of Integra dermal regeneration template for burn treatment. J. Burn Care Rehabil. 24: 42-48.
60. Hofman K, Primack A, Keusch G, Hrynkow S (2005). Addressing the growing burden of trauma and injury in low- and middle-income countries. Am. J Public Health 95: 13-17.
61. Huang H, Chen L, Wang H, Xiu B, Li B, Wang R, Zhang J, Zhang F, Gu Z, Li Y, Song Y, Hao W, Pang S, Sun J (2003). Influence of patients' age on functional recovery after transplantation of olfactory ensheathing cells into injured spinal cord injury. Chin. Med. J. (Engl.) 116: 1488-1491.
62. Hüsing B, Bührlen B, Gaisser S (2003). Human tissue engineered products: today's market and future prospects; final report for work package 1: analysis of the actual market situation - mapping of industry and products. Karlsruhe, Germany, Fraunhofer Institute for Systems and Innovation Research.
63. Jamison DT, Breman JG, Measham AR, Alleyne G, Evans DB, Jha P, Mills A, Musgrove P (2006). Disease Control Priorities in Developing Countries, The World Bank and Oxford University Press, New York, NY.
64. Johnsen S, Ermuth T, Tanczos E, Bannasch H, Horch RE, Zschocke I, Peschen M, Schopf E, Vanscheidt W, Augustin M (2005). Treatment of therapy-refractive ulcera cruris of various origins with autologous keratinocytes in fibrin sealant. Vasa 34: 25-29.
65. Jones I, Currie L, Martin R (2002). A guide to biological skin substitutes. Br. J. Plast. Surg 55: 185-193.
66. Josimović-Alasevic O, Fritsch KG (2001). co.don Geschäftsbericht. Teltow, Germany, co.don.
67. Kaiser S (2006). Tissue engineered products: need and requirements for an appropriate harmonized EU regulatory framework. Faculty of Mathematics and Natural Sciences, University of Bonn, Germany.
68. Kang HJ, Kim HS, Zhang SY, Park KW, Cho HJ, Koo BK, Kim YJ, Soo LD, Sohn DW, Han KS, Oh BH, Lee MM, Park YB (2004). Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 363: 751-756.
69. Knoller N, Auerbach G, Fulga V, Zelig G, Attias J, Bakimer R, Marder JB, Yoles E, Belkin M, Schwartz M, Hadani M (2005). Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results. J. Neurosurg. Spine 3: 173-181.
70. Kuddus R, Patzer JF, Lopez R, Mazariegos GV, Meighen B, Kramer DJ, Rao AS (2002). Clinical and laboratory evaluation of the safety of a bioartificial liver assist device for potential transmission of porcine endogenous retrovirus. Transplantation 73: 420-429.
71. Kuiters F, Doering F (2005). Cytroi Therapeutics: the future leader in regenerative medicine. San Diego, Junge Füchse.
72. Kumar RJ, Kimble RM, Boots R, Pegg SP (2004). Treatment of partial-thickness burns: a prospective, randomized trial using Transcyte. ANZ. J. Surg 74: 622-626.
73. Lamm P, Juchem G, Wolf H, Milz S, Schuffenhauer M, Reichart B (2003). Tissue-engineered conduits for aortocoronary bypass grafting. 32nd Annual Meeting of the German Society for Thoracic and Cardiovascular Surgery; Leipzig. Stuttgart, Germany, Georg Thieme Verlag.
74. Litzke LE, Wagner E, Baumgaertner W, Hetzel U, Josimovic-Alasevic O, Libera J (2004). Repair of extensive articular cartilage defects in horses by autologous chondrocyte transplantation. Ann. Biomed. Eng. 32: 57-69.
75. Lysaght MJ, Hazlehurst AL (2004). Tissue engineering: the end of the beginning. Tissue Eng. 10: 309-320.
76. Marcacci M, Berruto M, Brocchetta D, Delcogliano A, Ghinelli D, Gobbi A, Kon E, Pederzini L, Rosa D, Sacchetti GL, Stefani G, Zanasi S (2005). Articular cartilage engineering with Hyalograft C: 3-year clinical results. Clin. Orthop. Relat. Res. 96-105.
77. Marston WA (2004). Dermagraft, a bioengineered human dermal equivalent for the treatment of chronic nonhealing diabetic foot ulcer. Expert. Rev. Med Devices 1: 21-31.
78. Mathieson M (2005). Technology-based economic development capabilities. Arlington, VA, Center for Science, Technology & Economic Development, SRI International.
79. Matsumura G, Hibino N, Ikada Y, Kurosawa H, Shin'oka T (2003). Successful application of tissue engineered vascular autografts: clinical experience. Biomaterials 24: 2303-2308.
80. Mazariegos GV, Kramer DJ, Lopez RC, Shakil AO, Rosenbloom AJ, DeVera M, Giraldo M, Grogan TA, Zhu Y, Fulmer ML, Amiot BP, Patzer JF (2001). Safety observations in phase I clinical evaluation of the Excorp Medical Bioartificial Liver Support System after the first four patients. ASAIO J. 47: 471-475.
81. Mazariegos GV, Patzer JF, Lopez RC, Giraldo M, Devera ME, Grogan TA, Zhu Y, Fulmer ML, Amiot BP, Kramer DJ (2002). First clinical use of a novel bioartificial liver support system (BLSS). Am. J. Transplant. 2: 260-266.
82. McIntire LV (2003). WTEC panel report on tissue engineering. Tissue Eng 9: 3-7.
83. McIntire LV, Greisler HP, Griffith L, Johnson PC, Mooney DJ, Mrksich M, Parenteau NL, Smith D (2002). Tissue Engineering Research, International Technology Research Institute, Baltimore, Maryland.
84. Meinhart JG, Deutsch M, Fischlein T, Howanietz N, Froschl A, Zilla P (2001). Clinical autologous in vitro endothelialization of 153 infrainguinal ePTFE grafts. Ann. Thorac. Surg 71: S327-S331.
85. Melnikova I (2006). Promise of Stem Cell Therapy: Challenges and Opportunities, MEDACorp, Boston, MA.
86. Millis JM, Cronin DC, Johnson R, Conjeevaram H, Conlin C, Trevino S, Maguire P (2002). Initial experience with the modified extracorporeal liver-assist device for patients with fulminant hepatic failure: system modifications and clinical impact. Transplantation 74: 1735-1746.
87. Millis M, Maguire P, Cronin D, Conjeevarum H, Johnson R, Conlin C, Brotherton J, O'Laughlin R, Triglia D, Piazza R (1999). Continuous human liver support as a bridge to transplantation. Hepatology 30: 168A.
88. Monstrey S, Beele H, Kettler M, Van Landuyt K, Blondeel P, Matton G, Naeyaert JM (1999). Allogeneic cultured keratinocytes vs. cadaveric skin to cover wide-mesh autogenous split-thickness skin grafts. Ann. Plast. Surg. 43: 268-272.
89. Moustafa M, Simpson C, Glover M, Dawson RA, Tesfaye S, Creagh FM, Haddow D, Short R, Heller S, MacNeil S (2004). A new autologous keratinocyte dressing treatment for non-healing diabetic neuropathic foot ulcers. Diabet. Med 21: 786-789.
90. Naito Y, Imai Y, Shin'oka T, Kashiwagi J, Aoki M, Watanabe M, Matsumura G, Kosaka Y, Konuma T, Hibino N, Murata A, Miyake T, Kurosawa H (2003). Successful clinical application of tissue-engineered graft for extracardiac Fontan operation. J. Thorac. Cardiovasc. Surg 125: 419-420.
91. Neuronyx (2006). Safety Study of Bone Marrow Derived Cells to Treat Damaged Heart Muscle. A clinical trial listed in ClinicalTrials.gov website of National Institute of Health of USA. CLP-05-018.
92. Noordenbos J, Dore C, Hansbrough JF (1999). Safety and efficacy of TransCyte for the treatment of partial-thickness burns. J. Burn Care Rehabil. 20: 275-281.
93. Novocell (2006). Safety and efficacy of PEG-encapsulated islet allografts implanted in type I diabetic recipients. A clinical trial listed in ClinicalTrials.gov web site of National Institute of Health of USA. Study ID Numbers: NC-PCIA-04-001; WIRB #20041068.
94. Omar AA, Mavor AI, Jones AM, Homer-Vanniasinkam S (2004). Treatment of venous leg ulcers with Dermagraft. Eur. J. Vasc. Endovasc. Surg. 27: 666-672.
95. Pagani FD, DerSimonian H, Zawadzka A, Wetzel K, Edge AS, Jacoby DB, Dinsmore JH, Wright S, Aretz TH, Eisen HJ, Aaronson KD (2003). Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. J. Am. Coll. Cardiol. 41: 879-888.
96. Parente S (1997). Estimating the economic cost offset of using dermagraft-TC as an alternative to cadaver allograft in the treatment of graftable burns. J Burn Care Rehabil. 18: 18-24.
97. Park HC, Shim YS, Ha Y, Yoon SH, Park SR, Choi BH, Park HS (2005). Treatment of complete spinal cord injury patients by autologous bone marrow cell transplantation and administration of granulocyte-macrophage colony stimulating factor. Tissue Eng. 11: 913-922.
98. Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Mesquita CT, Rossi MI, Carvalho AC, Dutra HS, Dohmann HJ, Silva GV, Belem L, Vivacqua R, Rangel FO, Esporcatte R, Geng YJ, Vaughn WK, Assad JA, Mesquita ET, Willerson JT (2003). Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 107: 2294-2302.
99. Russell J, Cross S (2001). Commercial Prospects for Tissue Engineering. Business Intelligence Program-SRI Consulting.
100. Saberi H, Firoozi M, Moshayedi P (2006). Preliminary results of Schwann cell transplantation for chronic spinal cord injuries. Chicago, Illinois, Congress of Neurological Surgeons. 2006 Congress of Neurological Surgeons Annual Meeting. 2006.
101. Sauer IM, Kardassis D, Zeillinger K, Pascher A, Gruenwald A, Pless G, Irgang M, Kraemer M, Puhl G, Frank J, Muller AR, Steinmuller T, Denner J, Neuhaus P, Gerlach JC (2003a). Clinical extracorporeal hybrid liver support - phase I study with primary porcine liver cells. Xenotransplantation. 10: 460-469.
102. Sauer IM, Zeilinger K, Pless G, Kardassis D, Theruvath T, Pascher A, Goetz M, Neuhaus P, Gerlach JC (2003b). Extracorporeal liver support based on primary human liver cells and albumin dialysis - treatment of a patient with primary graft non-function. J. Hepatol. 39: 649-653.
103. Schachinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C, Abolmaali ND, Vogl TJ, Hofmann WK, Martin H, Dimmeler S, Zeiher AM (2004). Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J. Am. Coll. Cardiol. 44: 1690-1699.
104. Schmelzeisen R, Schimming R, Sittinger M (2003). Making bone: implant insertion into tissue-engineered bone for maxillary sinus floor augmentation-a preliminary report. J. Craniomaxillofac. Surg 31: 34-39.
105. Senker J, Mahdi S (2003). Human tissue engineered products: today's market and future prospects; research activities and future developments of human tissue engineering in Europe and the US. Brighton, SPRU Science and Technology Policy Research, University of Sussex.
106. Shin'oka T, Imai Y, Ikada Y (2001). Transplantation of a tissue-engineered pulmonary artery. N. Engl. J. Med. 344: 532-533.
107. Silberglitt R, Antón PS, Howell DR, Wong A (2006). The Global Technology Revolution 2020, In-Depth Analyses: Bio/Nano/Materials/Information Trends, Drivers, Barriers, and Social Implications, RAND Corporation, Pittsburgh, PA.
108. Siminiak T, Fiszer D, Jerzykowska O, Grygielska B, Rozwadowska N, Kalmucki P, Kurpisz M (2005). Percutaneous trans-coronary-venous transplantation of autologous skeletal myoblasts in the treatment of post-infarction myocardial contractility impairment: the POZNAN trial. Eur. Heart J. 26: 1188-1195.
109. Skalak R, Fox CF (1988). Tissue Engineering: Proceedings of a Workshop Held at Granlibakken, Lake Tahoe, California, February 26-29, 1988, Alan Liss, New York.
110. Smith RM, Gale EA (2005). Survival of the fittest? Natural selection in islet transplantation. Transplantation 79: 1301-1303.
111. Smits PC, van Geuns RJ, Poldermans D, Bountioukos M, Onderwater EE, Lee CH, Maat AP, Serruys PW (2003). Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J. Am. Coll. Cardiol. 42: 2063-2069.
112. Soler C (2002). Genevrier Biotechnology Center: production of autologous epidermal sheets (Epibase). Ann. Dermatol. Venereol. 129: 1239-1241.
113. Stamm C, Westphal B, Kleine HD, Petzsch M, Kittner C, Klinge H, Schumichen C, Nienaber CA, Freund M, Steinhoff G (2003). Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 361: 45-46.
114. StemCells Inc (2006). Study of the safety and preliminary effectiveness of human central nervous system (CNS) stem cells (HuCNS-SC) in patients with infantile or late infantile neuronal ceroid lipofuscinosis (NCL). A clinical trial listed in ClinicalTrials.gov web site of National Institute of Health of USA. Study ID Numbers: CL-N001-05.
115. Still J, Glat P, Silverstein P, Griswold J, Mozingo D (2003). The use of a collagen sponge/living cell composite material to treat donor sites in burn patients. Burns 29: 837-841.
116. Still JM, Orlet HK, Law EJ (1994). Use of cultured epidermal autografts in the treatment of large burns. Burns 20: 539-541.
117. Strauer BE, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg RV, Kogler G, Wernet P (2002). Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106: 1913-1918.
118. Strietzel FP (2006). Tissue-engineered bone for lateral alveolar ridge augmentation: a case report. Int. J. Oral Maxillofac. Implants. 21: 131-135.
119. Sussman NL, Gislason GT, Conlin CA, Kelly JH (1994). The Hepatix extracorporeal liver assist device: initial clinical experience. Artif. Organs 18: 390-396.
120. Syková E, Jendelová P, Urdzíková L, Lesný P, Hejcl A (2006). Bone Marrow Stem Cells and Polymer Hydrogels-Two Strategies for Spinal Cord Injury Repair. Cell Mol. Neurobiol.
121. Szycher M (2002). CardioPass coronary artery bypass graft: a progress report. Wilmington, MA, CardioTech International, Inc.
122. Tausche AK, Skaria M, Bohlen L, Liebold K, Hafner J, Friedlein H, Meurer M, Goedkoop RJ, Wollina U, Salomon D, Hunziker T (2003). An autologous epidermal equivalent tissue-engineered from follicular outer root sheath keratinocytes is as effective as split-thickness skin autograft in recalcitrant vascular leg ulcers. Wound. Repair Regen. 11: 248-252.
123. Vaillant L (2002). Treatment of venous leg ulcers with Epibase. A prospective study. Preliminary results. Ann. Dermatol. Venereol. 129: 1245-1246.
124. Vanlauwe J (2005). An international multicentric prospective randomized controlled trial for cartilage repair using microfracture versus autologous chondrocyte implantation with ChondroCelect®: scientific background and trial design. Proceedings of Annual Flemish Biotech Convention: Knowledge for Growth. Gnet, Belgium, FlandersBio. 2005.
125. Vibe-Hansen R, Aesculai S (1998). Methods, instruments and kit for autologous chondrocyte transplantation. Patent WO 98/08469.
126. Watanabe FD, Mullon CJ, Hewitt WR, Arkadopoulos N, Kahaku E, Eguchi S, Khalili T, Arnaout W, Shackleton CR, Rozga J, Solomon B, Demetriou AA (1997). Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann. Surg 225: 484-491.
127. Westerhof W, Lontz W, Vanscheidt W, Braathen L (2001). Vitiligo: news in surgical treatment. J. Eur. Acad. Dermatol. Venereol. 15: 510-511.
128. Wild S, Roglic G, Green A, Sicree R, King H (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053.
129. Williams DF (2003). The Japanese Approach to Tissue Engineering, The Royal Academy of Engineering, London.
130. Winfrey ME, Cochran M, Hegarty MT (1999). A new technology in burn therapy: INTEGRA artificial skin. Dimens. Crit Care Nurs. 18: 14-20.
131. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arseniev L, Hertenstein B, Ganser A, Drexler H (2004). Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364: 141-148.
132. Wright KA, Nadire KB, Busto P, Tubo R, McPherson JM, Wentworth BM (1998). Alternative delivery of keratinocytes using a polyurethane membrane and the implications for its use in the treatment of full-thickness burn injury. Burns 24: 7-17.